bioihbjkbjnl/mcl2 huggingface dataset:
A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue
Condition: Breast Cancer; Fatigue
MeSH terms: Breast Neoplasms; Fatigue
Study type: Interventional

Summary: 
      This randomized controlled trial will compare the effectiveness of an Iyengar Yoga
      intervention to a Wellness Seminar health education lecture series, for improvements in
      energy, mood and biological functioning in breast cancer survivors with persistent,
      post-treatment fatigue. It is anticipated that the Iyengar Yoga intervention will be feasible
      and acceptable to breast cancer survivors with minimal side effects and that the Yoga
      intervention will be effective in improving fatigue and physical performance.
    

Detailed description: 
      Fatigue is the most common and distressing side effect of cancer treatment and persists
      beyond successful treatment completion in approximately 30% of breast cancer survivors,
      causing serious disruption in quality of life. Behavioral interventions incorporating
      physical activity or relaxation/stress management have demonstrated beneficial effects on
      cancer-related fatigue, although research in cancer survivors is limited. Mind-body
      interventions such as yoga are extremely popular among cancer patients and offer a promising
      alternative to traditional treatments. Research is needed to establish the feasibility and
      efficacy of these interventions in cancer populations, particularly those who are
      experiencing problems with fatigue.
    

Intervention name(s): Iyengar Yoga; Wellness Seminar Series
Intervention type(s): Other; Other
Intervention description(s): The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.; The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
Other intervention name(s): Yoga; Health education
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: Breast Cancer; Fatigue; Proinflammatory Cytokines; Physical functioning; Quality of life
Preference and Goal Directed Attention Deficit Hyperactivity Disorder Care- Pilot Study
Condition: Attention Deficit Hyperactivity Disorder
MeSH terms: Hyperkinesis; Attention Deficit Disorder with Hyperactivity
Study type: Interventional

Summary: 
      This pilot intervention study will test the feasibility and acceptability and explore the
      outcomes of an urban, primary care-based intervention to measure families' preferences and
      goals for Attention-Deficit/Hyperactivity Disorder (ADHD) treatment and structure clinical
      care to reach these goals.
    

Detailed description: 
      The intervention includes provision of enhanced, culturally appropriate education about ADHD
      and its treatment, completion of a validated preference and goal instrument, use of this
      instrument in the ADHD treatment decision-making process, and tracking of preferences and
      goals over time.
    

Intervention name(s): Preference and Goal Instrument
Intervention type(s): Other
Intervention description(s): Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Attention Deficit Hyperactivity Disorder; ADHD; Preferences; Goals; Decision Making
Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines
Condition: Wrinkles
Study type: Interventional
Phase: Phase 3

Summary: 
      The dermatological treatment for reducing facial wrinkles with injectable drug Botulift
      (botulinum toxin type A - Laboratório Químico Farmacêutico BergamoLtd.) has a not inferior
      activity when compared with Botox ® (botulinum toxin - Allergan Inc.) in clinical trials.
    

Detailed description: 
      The study will evaluate non-inferiority in clinical improvement in the intensity of
      expression lines over 16 weeks of drug Botulift (Laboratório Químico Farmacêutico Bergamo
      Ltd.) compared with Botox ® (Allergan Inc.). So that the homogeneity of the group opted to
      use in female patients with glabellar wrinkles grade 2 (moderate) and 3 (severe) Scale
      Standard Facial Wrinkles, established by Honecker et al. (2003). The first area of the face
      perceived in mime is the glabellar complex, located in the space between the eyebrows,
      wrinkles eventually show (Almeida et al., 2010).

      Patients will be evaluated at each visit, the doctor Principal Investigator and digital
      photos of the glabellar region at maximum contraction and relaxation will be obtained using
      the apparatus Visia (Canfield Imaging Systems, version 4.0.2) for further analysis by random
      team dermatologists.
    

Intervention name(s): Botulift; Botox
Intervention type(s): Drug; Drug
Intervention description(s): Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).; Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
Other intervention name(s): Botulinum Toxin Type A; Botulinum Toxin Type A
Intervention MeSH terms: Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Wrinkles, glabellar, facial.
To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.
Condition: Decompensated Cirrhosis
MeSH terms: Fibrosis
Study type: Interventional

Summary: 
      All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016. Decompensated
      cirrhosis patients will be randomized into Group 1: MVP (Moderate Volume Paracentesis) of
      less than 5 litres with iv albumin at a dose 8 gms/l of ascitic fluid Group 1: MVP (Moderate
      Volume Paracentesis) of less than 5 litres without albumin .
    


Intervention name(s): Albumin; ascitic fluid
Intervention type(s): Drug; Drug
Intervention description(s): MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT
Condition: HIV Infections
MeSH terms: Infections; HIV Infections; Acquired Immunodeficiency Syndrome
Study type: Interventional
Phase: Phase 2

Summary: 
      PRIMARY: To determine safety, tolerance, and pharmacokinetics of zidovudine (AZT) and
      zalcitabine (dideoxycytidine; ddC) when given in combination in clinically stable AZT-treated
      children.

      SECONDARY: To compare combination therapy with mono drug therapy for antiviral activity and
      laboratory markers of disease progression, as determined by virologic and immunologic
      determinations. To evaluate the influence of combination therapy on disease progression as
      determined by evaluation of clinical criteria.

      In children currently being treated with AZT, it is unknown whether the addition of another
      antiretroviral agent such as ddC would help increase efficacy and tolerance. This study will
      examine the possible advantages of combination AZT/ddC therapy over monotherapy with AZT
      alone.
    

Detailed description: 
      In children currently being treated with AZT, it is unknown whether the addition of another
      antiretroviral agent such as ddC would help increase efficacy and tolerance. This study will
      examine the possible advantages of combination AZT/ddC therapy over monotherapy with AZT
      alone.

      Patients are stratified according to duration of ongoing AZT therapy and are randomized to
      receive AZT either alone or in combination with ddC. Patients receive therapy until the last
      patient enrolled completes 32 weeks of therapy. The study may be extended for two additional
      32-week periods on an optional basis.
    

Intervention name(s): Zidovudine; Zalcitabine
Intervention type(s): Drug; Drug
Intervention MeSH terms: Zidovudine; Zalcitabine
Primary purpose: Treatment
Keywords: Zalcitabine; Drug Therapy, Combination; Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Zidovudine
Functional and Proprioceptive Status in Patients With Hemophilic Ankle Arthropathy
Condition: Haemophilia
MeSH terms: Joint Diseases
Study type: Observational

Summary: 
      Introduction: Hemophilic ankle arthropathy is manifested by functional degenerative
      alterations (muscle strength deficit, mobility and proprioception), intra-articular and
      chronic pain.

      Design: Case-control study. Objective: To observe the differences between patients with
      hemophilic ankle arthropathy and their healthy peers, regarding dorsiflexion, dorsiflexion
      strength, biomechanical analysis of gait and balance, and functionality.

      Patients: 10 patients with hemophilic ankle arthropathy and 12 healthy subjects without ankle
      joint damage.

      Measurement instruments and study variables: dorsiflexion (range of motion), dorsiflexion
      strength (dynamometry), biomechanical analysis of gait and balance (RS SCAN® model platform),
      and functionality (2 Minute Walk Test).

      Expected results: Analyze the main differences and their relationship based on the clinical
      and independent variables of patients with hemophilia, compared to their healthy peers.
    


Intervention name(s): Hemophilia group
Intervention type(s): Other
Intervention description(s): Evaluation of the study variables: dorsal flexion; dorsiflexion strength; tibialis anterior muscle activation; biomechanical analysis of gait and balance; and functionality.
Observational model: Case-Control
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        Patients with hemophilic ankle arthropathy older than 18 years (group of cases). Healthy
        subjects without ankle joint damage, of the same age range (control groups).
      
Keywords: Hemophilic arthropathy; Ankle; Joint pain; Functionality; Range of motion; Proprioception
Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?
Condition: Coronary Artery Disease
MeSH terms: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
Study type: Interventional

Summary: 
      We are studying the affect of caffeine on the sensitivity of detecting coronary artery
      disease (blockages in the blood flow to the heart) with adenosine tracer scans. Adenosine is
      a drug used routinely in patients to relax heart blood vessels in order to assess for the
      presence of coronary artery disease. Often, if patients have had caffeine, the adenosine scan
      is not used because of the belief that caffeine may reduce the ability to detect coronary
      artery disease. We would like to test whether caffeine affects our ability to detect coronary
      artery disease with adenosine tracer scanning. We will perform an imaging study of the heart
      with adenosine after you have received caffeine.
    


Intervention name(s): Cardiac SPECT imaging Rest and Stress; Caffeine; Caffeine
Intervention type(s): Procedure; Drug; Drug
Intervention description(s): adenosine perfusion scintigraphy; Caffeine 400 mg po; Caffeine 200 mg po
Intervention MeSH terms: Caffeine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: adenosine tracer scans; coronary artery disease; caffeine
Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation
Condition: Graft-versus-host Disease; Survival
MeSH terms: Graft vs Host Disease
Study type: Interventional
Phase: Phase 3

Summary: 
      To evaluate if rapamune + tacrolimus immunosuppressive prophylaxis is better than the
      established therapy using cyclosporine and methotrexate, a Nordic prospective multicenter
      randomized study will be performed. Patients will be randomized to treatment with rapamune
      combined with tacrolimus, or the established therapy using cyclosporine and methotrexate.
    

Detailed description: 
      Primary endpoint The primary endpoint is grade II-IV acute GVHD in the two groups. GVHD is
      diagnosed clinically and graded from 0 to IV. The diagnosis is clinical and biopsies from
      skin, liver and gut is used according to the routines at each participating center.

      Other study parameters

        1. Time to neutrophils >0.5 x 109/L.

        2. Time to platelets >20 x 109/L and 50 x 109/L.

        3. Platelet level 30 days after transplant.

        4. Transfusion requirements of platelets, erythrocytes, granulocyte transfusions during the
           first 30 days.

        5. Non-engraftment (graft failure/rejection).

        6. Grade of acute GVHD.

        7. Incidence of chronic graft-versus-host disease graded as limited or extensive and mild,
           moderate and severe.

        8. Transplant-related mortality.

        9. Probability of relapse in patients with haematological malignancies.

       10. Survival.

       11. Relapse-free survival.

       12. Infections by bacteria, virus and fungi. Cytomegalovirus reactivation is also followed
           by PCR.

       13. Side-effects. Side-effects regarding hematopoiesis, liver test, renal function, cardiac
           function, neurology, endocrinology, etc., are taken from the patients' charts. These
           parameters are followed regularly after transplantation.

      Inclusion criteria Chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid
      leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete
      remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant
      disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders
    

Intervention name(s): Sirolimus/tacrolimus; cyclosporine/methotrexate
Intervention type(s): Drug; Drug
Intervention description(s): Standard GVHD prophylaxis; Standard GVHD prophylaxis
Intervention MeSH terms: Cyclosporine; Sirolimus; Methotrexate; Tacrolimus; Cyclosporins
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: GVHD; tacrolimus; sirolimus; cyclosporine; allogeneic; stem cell transplantation; Relapse-free survival
Prevalence of Presenting Diseases for Elderly Patients Admitted to Emergency Department
Condition: Geriatric Disorder
MeSH terms: Emergencies
Study type: Observational

Summary: 
      The number of elderly patients admitted to the Emergency Department (ED) is dramatically
      increasing.
    

Detailed description: 
      The number of elderly patients admitted to the Emergency Department (ED) is dramatically
      increasing. Most emergency physicians have not been trained in specific geriatric approaches,
      and many report being less comfortable when dealing with older patients. Aim of this study is
      the investigation the most common conditions affecting older patients in the ED.
    

Intervention name(s): Elderly patients
Intervention type(s): Other
Intervention description(s): Elderly patients who visited the Emergency Department
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Elderly patients who visited the Emergency Department of Adiyaman University of Training
        and Research Hospital between 1 January 2015 and 1 December 2015.
      
Keywords: elderly patients; prevalence; emergency department use; main presenting disease
Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
Condition: Idiopathic Short Stature
MeSH terms: Dwarfism
Study type: Interventional
Phase: Phase 3

Summary: 
      Growth hormone therapy will improve the height of idiopathic short statured children.
      DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to
      non-treatment group in efficacy and safety.
    


Intervention name(s): DA-3002
Intervention type(s): Drug
Other intervention name(s): Recombinant Human Growth Hormone
Intervention MeSH terms: Hormones
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: growth hormone
Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer
Condition: Cervical Cancer
MeSH terms: Uterine Cervical Neoplasms
Study type: Interventional

Summary: 
      Background/Purpose: This is a large scale, multicenter randomized clinical trial to assess
      the feasibility of using SurePath® in cervical cancer patients after radiation therapy by
      comparing the incidence of unsatisfactory smear and the accuracy of detecting cervicovaginal
      lesions between the SurePath® and the conventional smear.

      Patients and Methods: The investigators will invite all women who had received radiotherapy
      for cervical cancer in the investigators outpatient clinics. All enrolled cases will ask to
      receive randomly the SurePath® or the conventional smear.

      Expected Results: The investigators will get the incidence of unsatisfactory smear and the
      accuracy of detecting cervicovaginal lesions between the SurePath® and the conventional smear
      in patients who underwent radiotherapy.
    

Detailed description: 
      Adequate specimen (specimen adequacy) is cervical or vaginal cytology single most important
      quality factors. 2001 Pap Bethesda System classification maintain its previous version, the
      Pap specimen is divided into satisfactory assessment and unsatisfactory evaluation two kinds;
      meet "satisfactory assessments "specimen standard, conventional Pap (conventional smear)
      requires at least 8,000-12,000-readable squamous cells, and liquid-based Pap (liquid-based
      smear) you need at least 5,000-readable squamous cell .

      For squamous cell samples were determined to be adequate, yet to record their specimens have
      intrauterine neck or squamous transitional zone (transformation zone) border zone cells
      exist; quality indicators "Cell interpretation in part by inflammation or blood masking noise
      "of the specimen, if it can not be sentenced to 50-75% of epithelial cells can still be
      classified as read" satisfied "with the specimen, while more than 75% of the epithelial cells
      are obscured interference specimen is classified in the" unsatisfactory "specimen.
    

Intervention name(s): Surepath; Conventional Pap smear
Intervention type(s): Device; Device
Intervention description(s): A liquid-base method of Pap smear for screening the recurrence of cervical cancer; Conventional Pap smear
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Screening
Eszopiclone in the Treatment of Insomnia and Fibromyalgia
Condition: Fibromyalgia; Insomnia
MeSH terms: Fibromyalgia; Myofascial Pain Syndromes; Sleep Initiation and Maintenance Disorders
Study type: Interventional
Phase: Phase 4

Summary: 
      The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other
      symptoms of fibromyalgia. It is hypothesized that participants receiving eszopiclone will
      report greater improvement in total sleep time, sleep quality, pain, fatigue, physical
      functioning, and emotional distress than will those receiving placebo.
    

Detailed description: 
      Fibromyalgia (FM) is a prevalent, debilitating, and costly syndrome. Although the
      pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of
      most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia, but
      has not been studied in the treatment of FMS. The purpose is to assess the efficacy of
      eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia (FMS) in FMS
      patients. Participants will be randomly selected to receive eszopiclone or placebo. It is
      hypothesized that participants receiving eszopiclone will report greater improvement in total
      sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than
      will those receiving placebo.
    

Intervention name(s): Eszopiclone; placebo
Intervention type(s): Drug; Drug
Intervention description(s): 3mg qpm for 12 weeks; 1 pill qpm for 12 weeks
Other intervention name(s): Lunesta
Intervention MeSH terms: Eszopiclone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Fibromyalgia; Insomnia; Sleep; Eszopiclone; Lunesta
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
Condition: Allergic Asthma
MeSH terms: Asthma; Airway Obstruction
Study type: Interventional
Phase: Phase 2

Summary: 
      This was a multicenter, randomized, double-blind, parallel-group, three-arm,
      placebo-controlled study designed to demonstrate the efficacy of two different formulations
      of omalizumab compared with placebo in reducing the airway reaction to an inhaled
      aeroallergen solution in adult subjects with mild allergic asthma.
    


Intervention name(s): omalizumab; omalizumab; placebo
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Aged Liquid; subcutaneous repeating dose; Lyophilized; subcutaneous repeating dose; Subcutaneous repeating dose
Intervention MeSH terms: Omalizumab; Antibodies, Monoclonal
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: AQUA; anti-CD11; CD11a; Asthma; Allergy